Loading stock dossier…
Panacea Biotec Limited is a mid-cap Healthcare stock. The composite smart-money score (insider + FII/DII flow + block deals + mutual-fund accumulation) is currently in the "NEUTRAL" bucket.
Up to 10 years of daily closes, with vertical hairlines marking the dates of earnings announcements (accent), ownership inflections (red), and dividend ex-dates (faint). Hover any hairline for the event label.
Hover the chart for a date+price readout; click any vertical hairline to pin its event label.
| 2020 | — | |||
| 2019 | — | — | — | — |
| 2018 | — | — | — | — |
| 2017 | — | — | — | — |
One rupee invested at the start, plotted on a log scale, with closes back-adjusted for every stock split and bonus issue across the window. The headline reads the cumulative outcome; the CAGR badge annualises it.
Every historical drawdown of 12% or more in the available 10 years of EOD data. The left bar shows depth; the right bar shows months until the price made a new all-time high.
Two views of recent event-driven price action: the earnings-reaction grid shows how the market traded the day after each of the last 8 quarterly results, and the insider heat strip shows weekly net insider buying/selling over the last 90 days.
Every Indian mutual fund that disclosed a position in PANACEABIO on its latest monthly portfolio sheet, grouped by AMC. Box size scales with the absolute rupee value held.
Box size ∝ holding market value. Outer blocks are AMCs; inner blocks are individual schemes. Latest monthly disclosure.
Aggregated from the latest monthly portfolio disclosures across all Indian MFs. HHI (Herfindahl-Hirschman Index) is computed at the AMC level — an HHI above 2500 indicates concentrated MF ownership across few fund houses.
| Date | Insider | Category | Type | Qty |
|---|
Equity prices and ratios are computed from NSE / BSE end-of-day data. No content on this page constitutes a buy / sell / hold recommendation. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
No signal at present — see methodology for the criteria.
No signal at present — see methodology for the criteria.
No signal at present — see methodology for the criteria.
SWOT items are auto-derived from quantitative factor scores, Smart Money sentiment, and shareholding snapshot. They are not investment advice.
Each factor is computed monthly from the in-house model and bucketed into quintiles across the active equity universe. Q1 = top quintile on that factor (favourable position) · Q5 = bottom quintile.
T+1 = close one trading session after the result announcement (or next trading day).
Insider transactions grouped by week, net of buys vs sells in rupee value. Colour saturation scales to the largest-net week in the window. SEBI Reg 7(2) filings.
| Value |
|---|
| 1 Oct 2025 | Nosheen Sheikh | Immediate relative | BUY | 3,000 | ₹12L |
| 1 Jan 2025 | Sandeep Jain | Promoters | SELL | 5,000 | ₹20L |
| 31 Dec 2024 | Sandeep Jain | Promoters | SELL | 10,000 | ₹43L |
| 30 Dec 2024 | Rajesh Jain | Director | BUY | 3,000 | ₹14L |
| 25 Dec 2024 | Sandeep Jain | Promoters | SELL | 5,000 | ₹21L |
| 20 Dec 2024 | Sandeep Jain | Promoters | SELL | 5,000 | ₹23L |
| 17 Dec 2024 | Sandeep Jain | Promoters | SELL | 5,500 | ₹27L |
| 12 Dec 2024 | Sandeep Jain | Promoters | SELL | 5,500 | ₹26L |
| 4 Dec 2024 | Sandeep Jain | Promoters | SELL | 10,000 | ₹46L |
| 30 Nov 2024 | Sandeep Jain | Promoters | SELL | 10,000 | ₹42L |
| 26 Nov 2024 | Sandeep Jain | Promoters | SELL | 8,655 | ₹36L |
| 20 Nov 2024 | Sandeep Jain | Promoters | SELL | 54,000 | ₹2Cr |
| 1 Oct 2024 | Sandeep Jain | Promoters | SELL | 70,275 | ₹2Cr |